Shire Pulls US Drug Application, Blames FDA Delay

Law360, New York (March 15, 2012, 1:49 PM EDT) -- Irish pharmaceutical company Shire PLC said Wednesday that it has pulled its U.S. application for Replagal, which treats a rare and potentially life-threatening genetic disorder, because regulators would take too long to approve the drug.

The Dublin-based company has been in an ongoing dialogue with the U.S. Food and Drug Administration ever since Sanofi SA subsidiary Genzyme Corp. ran short of Fabrazyme, the only U.S.-approved treatment for Fabry disease. Genzyme announced the end of the shortage early this month, when it began shipping the product from...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.